INTRODUCTION

Lymphomas are a heterogeneous group of malignancies of the immune system. Non-Hodgkin’s lymphoma (NHL) are a group of neoplasms that originate from the cells of the lymphoreticular system. They constitute 5% of all head and neck cancers. A 25-30% of NHLs present in extranodal sites with the gastrointestinal tract being the most frequent site followed by the head and neck region constituting 11-33% of the cases.

Parker and Jackson in 1939 were the first to propose that extranodal lymphomas arising at a primary site in bone offered a favorable prognosis. Among the jaw lesions, maxilla is more commonly affected than the mandible with a predilection for the posterior sites.

Diffuse large B-cell lymphoma (DLBCL) is considered to be the most common subtype of NHL including primary mandibular NHL. According to the World Health Organization (WHO) classification of neoplastic diseases of hematopoietic and lymphoid tissues, DLBCL accounts for 40% of the adult NHL’s. This heterogeneous group of lymphoid neoplasm is characterized by diverse spectrum of clinical and morphological features, response to therapy and survival.

DLBCL is characterized by diffuse proliferation of large neoplastic B lymphoid cells with nuclear size equal to or exceeding normal macrophage nuclei, or more than twice the size of a normal lymphocyte. DLBCL may arise de novo, as a primary tumor or as a result of progression and transformation of a less aggressive lymphoma of a lower grade such as lymphocytic, follicular or marginal lymphoma. Classification systems as elicited by Kiel, subdivided DLBCL based on its morphology into centroblastic and immunoblastic lymphomas. Centroblastic lymphoma is the most common subtype with better prognosis (and overall survival) when compared with immunoblastic and anaplastic variants of DLBCL.

We present a case of primary diffuse centroblastic variant of large B-cell lymphoma in the mandible with added review of literature.

CASE REPORT

A 55 year old male patient reported to the dental hospital in the year 2007 with a complaint of painless swelling in the lower right body of the mandible for the last 4 months. The swelling was insidious in onset and gradually increased in size.
Facial asymmetry was seen on the right side. Examination revealed a nontender, solitary diffuse swelling measuring 3.5 cm × 3.5 cm in the lower right body of the mandible. The swelling was fixed, firm to hard in consistency. Intraorally, the swelling extended from 44 to 48 regions obliterating the buccal vestibule, with buccal cortical plate expansion. Computed tomography (CT) of mandible showed an osteolytic lesion with soft tissue density in the right body of the mandible at the mental foramen region with break in the cortical plates both on buccal and lingual side [Figure 1]. Incisional biopsy showed the lesion to be composed of abnormal large lymphoid cells with high nuclear cytoplasmic ratio. These large lymphoid cells were arranged in diffuse pattern, with the large cells having coarse chromatin and inconspicuous nucleoli [Figure 2]. Mitotic figures were also evident. The above mentioned findings favored the diagnosis of DLBCL.

Investigations like chest X-ray, ultrasonography of abdomen and pelvis, and bone scan of whole body were done. Bone scan showed minimal increase in uptake in the right mandible anteriorly indicating slow bone destruction. There was no evidence of distant bone involvement. Clinical examination and investigations classified the disease under stage IAE. Following this, immunohistochemical analysis was done for the expression of pan B-cell markers like CD45 (leukocyte common antigen), CD20 (selective marker that recognizes a subpopulation of B-cells), and CD3 (marker for T-cells and natural killer cells). CD45 [Figure 3] and CD20 [Figure 4] were positive and CD3 was negative. Based on immunohistochemistry report the lesion was diagnosed as DLBCL of the mandible. Centroblastic, immunoblastic, T-cell/histiocytic-rich, anaplastic, and plasmablastic variants are the five histopathological subtypes of DLBCL according to WHO classification. Histopathological examination of our case revealed centroblastic variant of DLBCL with few immunoblast like cells. Centroblasts are large noncleaved cells, with round to oval centrally placed nuclei and peripherally located nucleoli [Figure 5]. They have moderate to scanty cytoplasm with fragmentation of nucleoli being quite common among these cells. Based on histopathological examination and immunohistochemistry study, the following lesions under differential diagnosis were ruled out; Hodgkin’s
Diffuse large cell lymphoma

Based on the final diagnosis, chemotherapy was advised by the oncologist and a total of six cycles were suggested at the gap of every 3 weeks. The treatment regimen followed was that of cyclophosphamide, hydroxydoxorubicin, oncovin, and prednisone (CHOP) therapy comprising of cyclophosphamide, doxorubicin, vincristine, and prednisolone. Patient is being examined periodically once in 2 months and he has had no recurrences from past 3 years and is disease free.

Review of literature

NHL arises primarily within the lymph nodes; however extranodal presentations are common in patients with NHL. Oral manifestations presented in only 3-5% of cases of NHL and are rarely the initial manifestation of the disease.[1]

Of the NHLs that occur in the oral cavity, 15-45% occur in the maxilla and mandible.[11] A review of oral NHL shows upper jaw maxilla (11%), mandible (8%), palatal soft tissue (8%), vestibule, and gingiva (7%) to be the most common locations.[12] Isolated mandibular NHL accounts for only 0.6% of the cases reported. Such cases when occur commonly mimick odontogenic infections leading to delay in diagnosis and therapy for the patients. To be classified as a primary NHL of bone there must be no evidence of visceral or lymphatic involvement and no distant metastases for at least 6 months following diagnosis.[3] The peak incidence for primary NHL of jaws is in the 4th-5th decade. Equal sex distribution is usually reported with few cases showing female predominance.[13] Mandibular NHL may involve any site with Gusenbauer et al.,’s series involving the body of the mandible followed by ramus, angle and symphysis region.[14] In our case, the patient had undergone extraction, following which he developed a nontender swelling in the right mandibular body. Some authors reported paresthesia (about 20-100% of cases) along the inferior alveolar nerve to be common in NHL involving the mandible.[13]

There are no pathognomonic radiographic features for NHL involving the mandible. Features of osteolysis are usually suggestive with other radiological findings of destruction of the alveolar bone, diffuse trabecular pattern, mottling appearance, and resorption of roots of teeth. CT scan of our case showed an osteolytic lesion with soft tissue density in the right body of mandible at the mental foramen region with break in the cortical plates involving both buccal and lingual cortical sides. Histology coupled with immunophenotyping and cytogenetic evaluation can suggest the subtypes of NHL and thus help in rendering prompt treatment and aid in better survival rates of lymphoma patients.

The primary NHL involving the mandible for most of the times is of intermediate to high grade malignancy although it tends to remain localized at times of diagnosis with stage IAE presentation.[13,15]

DLBCL constitutes a heterogeneous group of lymphoid neoplasm’s that is characterised by diverse spectrum of clinical and morphological features, response to therapy and survival. Morphologically DLBCLs replace the normal architecture of lymph nodes in a diffuse pattern. Neoplastic cells are at least twice the size of normal lymphocytes with vesicular nuclei, prominent nucleoli, and basophilic cytoplasm.[6] DLBCL may be arising de novo, or as a primary tumor or as a result of transformation of a less aggressive lymphoma of lower grade such as lymphocytic, follicular, or marginal lymphoma.[8]

Twenty-eight percent of DLBCL’s depict chromosomal translocations and molecular rearrangements such as translocation of t (14;8) (q32;q21) involving the Bel-2 gene. Several classification systems have categorized DLBCL into its morphologic and phenotypic variants in the past.

WHO Revised European American Lymphoma (REAL) classification of NHL according to clinical aggressiveness; groups DLBCL under the aggressive lymphomas.[1]

The 2001 WHO classification being an update of REAL classification is given below.[16]

DLBCL subtypes according to 4th edition of the WHO classification of tumors of the hemopoietic and lymphoid tissues.

**DLBCL, not otherwise specified (NOS)**

**Common morphologic variants**

- Centroblastic
- Immunoblastic
- Anaplastic
Rare morphologic variants
Molecular subgroups
• Germinatal center B-cell like (GCB)
• Activated B-cell like

Immunohistochemical subgroups
• CD5-positive DBCL
• GCB
• Non-germinatal center B-cell like (non-GCB)

BCLB subtypes/entities
• Primary mediastinal (thymic) large B-cell lymphoma
• T cell/histiocyte rich large B-cell lymphoma
• Intravascular large B-cell lymphoma
• Primary DBCL of the central nervous system (CNS)
• Primary cutaneous DBCL, leg type
• DBCL associated with chronic inflammation
• Anaplastic lymphoma kinase (ALK) positive DBCL
• Large B-cell arising in human herpes virus (HHV) 8-associated multicentric Castleman disease
• Plasmablastic lymphoma and primary effusion lymphoma

Borderline cases
B-cell lymphoma, unclassifiable with features intermediate between DBCL and Burkitt’s lymphoma.

B-cell lymphoma unclassifiable, with features intermediate between DBCL and classical Hodgkin lymphoma.

Histopathologically, our case was diagnosed as centroblastic variant having medium to large sized lymphoid cells with oval to round vesicular nucleus with fine chromatin and 24 membrane bound nuclei, the cytoplasm being amphophilic to basophilic. The tumor represented a monomorphic pattern with more than 90% comprising of centroblastic cells. Centroblastic DBCL being the most common variant is composed of cells that resemble their normal counterparts in the reactive germinal centers.8 Variable number of immunoblasts may be found admixed, but generally comprises less than 90% of the tumor cell population.7

Histopathology, immunohistochemistry, immunophenotyping, and genetic studies help to categorize DBCL further, in order to direct a specific regimen of therapy. DBCL usually express pan B-cell markers such as CD19, CD20, CD75, CD79a, PAX5, and CD22; but may lack one or more of these. Surface and or cytoplasmic immunoglobulins (IgM > IgG > IgA) can be demonstrated in 50-75% of cases.6,17 CD20 expression by B-cells from mature precursor B-cell until the preplasma cell stage of differentiation is highly specific for B-cell lineage and mostly DBCL show homogeneously bright staining for this as seen in our case.18

Bcl-6 is selectively expressed by germinal center B-cell like GCB cells in normal lymphoid tissues and in DBCL at about 57-100%, but with unclear biological significance with reports suggesting Bcl-6 expression related to oncogenesis.18,19

Prognosis
Patients with DLBCL have variable clinical courses and prognosis depending on many clinical, morphological, phenotypic, and genetic parameters. International prognostic index (IPI) is widely used as a predictive model in DLBCL patients of all ages and clinical stages. The IPI combines patient’s age with easily measured clinical parameters which can serve as surrogate markers of tumor burden. Performance status, extranodal involvement, serum lactate dehydrogenase levels, stage of disease, and Bsymptom status are significantly associated with survival.10

A 5 year disease free survival was 53.2% for patients with centroblastic and 26.9% for patients with immunoblastic NHL.10 Patients with germinal center B-cell like lymphoma had the highest 5 year survival rate. DLBCLs of germinal center B type have a better prognosis than those derived from activated B-cell type.6

Treatment
Early stage disease care in DLBCL patients involves either chemotherapy alone or a combination of chemotherapy and radiotherapy. The chemotherapy usually involves three cycles of CHOP. The role of surgery is severely limited in treatment of DBCL. Current treatment of DBCL usually begins with multiagent chemotherapy, typically CHOP as done in our present case with 6 cycles of CHOP.1,18 Recently, anti-CD20 monoclonal antibody (rituximab) has been added to this regimen and has been found to improve failure-free survival.14 With the well-accepted addition of rituximab to the typical large B-cell lymphoma chemotherapeutic regimen, a revalidation of any survival differences between large B-cell lymphoma subtypes is necessary. So far, only a few studies have been published and we need more investigations in this field.19

Localized (stage 1 and stage II) low grade extranodal lymphomas in the head and neck are treated primarily with radiotherapy. Patients with localized intermediate grade lymphomas should be treated with combination chemotherapy as done in our case. There is evidence that CHOP regimen could be curative for this subset of patients. Radiation therapy alone was the mainstay of treatment for these disorders until curative combination chemotherapies were developed. High grade and advanced stage NHL should be treated with aggressive chemotherapy regimen.3

Treatment options with combination chemotherapy alone CHOP had no recurrences seen in patients with NHL similar to our case.20
CONCLUSION

In this brief case report and review of literature we describe a case of DLBCL, which is a subtype of NHL making up about approximately 30% of all NHLs. Its occurrence in the mandible is very rare. Centroblastic variant of DLBCL is known to have a better prognosis and overall survival in patients as observed in the previous literature reported and the same has been observed in the present case reported.

REFERENCES

1. Mahima VG, Patil K, Raina A. Extranoal nonhodgkin’s lymphoma. An unfamiliar presentation in the oral cavity: A case report. Int J Clin Cases Invest 2010:1-6.
2. Razmpa E, Saedi B. Clinical features of extranodal presentation of non-hodgkin’s lymphoma in head and neck. Acta Medica Iranica 2009;47:489-92.
3. Hanna E, Wanamaker J, Adelstein D, Tubbs R, Lavertu P. Extranodal lymphomas of the head and neck. A 20-year experience. Arch Otalaryngol Head Neck Surg 1997;123:1318-23.
4. Eisenbud L, Sciubba J, Mir R, Sachs AS. Oral presentations in non-Hodgkin’s lymphoma: A review of thirty one cases. Part II. Fourteen cases arising in bone. Oral Surg Oral Med Oral Pathol 1984;57:272-80.
5. Adouani A, Bouguila J, Jbeloua Y, Ben Aicha M, Abdelali M, Hellali M, et al. B-cell lymphoma of the mandible: A case report. Clin Med Oncol 2008;2:445-50.
6. Dominis M, Dzebro S, Gasparov S, Pesut A, Kusec R. Diffuse large B-cell lymphoma and its variants. Croat Med J 2002;43:535-40.
7. Gurbuxani S, Anastasi J, Hyjek E. Diffuse large B-cell lymphoma-more than a diffuse collection of large b cells: An entity in search of a meaningful classification. Arch Pathol Lab Med 2009;133:1121-34.
8. Ioachim LH. Ioachim’s Lymph Node Pathology. 4th ed. Philadelphia: Lippincott; 2009. p. 423.
9. De Paep P, Achten R, Verhoef G, Wlodarska I, Stul M, Vanhentenrijk V, et al. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol 2005;23:7060-8.
10. Gorczyca W. Prognostic Markers in Hematologic Oncology. Francis and Taylor; 2006. p. 151.
11. Barber HD, Stewart JC, Baxter WD. Non hodgkins lymphoma involving the inferior alveolar canal and mental foramen: Report of a case. J Oral Maxillofac Surg 1992;50:1334-6.
12. Kemp S, Gallagher G, Kabani S, Noonan V, O’Hara C. Oral non-Hodgkin’s lymphoma review of the literature and world health organization classification with reference to 40 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:194-201.
13. Steinbacher MD, Dolan WR. Isolated non-Hodgkin’s lymphoma of the mandible. Oral Oncol 2006;42:182-9.
14. Gussenbauer AW, Katsikeris NF, Brown A. Primary lymphoma of the mandible: Report of a case. J Oral Maxillofac Surg 1990;48:409-15.
15. Piatelli A, Croce A, Tete S, Artese L. Primary non-Hodgkins lymphoma of the mandible: A case report. J Oral Maxillofac Surg 1997;55:1162-6.
16. Piccaluga PP, Bacci F, Sabatlini E, Rossi M, Gazzola A, Sapienza MR et al. Large cell non-Hodgkins lymphoma: What is new in the WHO classification? Hematology Meeting Reports 2009;3:43-5.
17. Jaffe ES. Pathology and genetics of tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 172-3.
18. Bhattacharyya I, Chehal HK, Cohen DM, Al-Quran SZ. Primary diffuse large B-cell lymphoma of the oral cavity: Germinal center classification. Head Neck Pathol 2010;4:181-91.
19. Jabłońska J, Jesionek-Kupnicka D. Usefulness of immunohistochemistry in Identification of prognostically important subgroups (GCB and ABC) in a heterogeneous group of diffuse large B-cell lymphomas: A review article. Pol J Pathol 2008;59:121.
20. Someya M, Sakata K, Nagakura H, Itou K, Nakata K, Oouchi A, et al. Three cases of diffuse large B-cell lymphoma of the mandible treated with radiotherapy and chemotherapy. Radiat Med 2005;23:296-302.